Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Precision Biosciences Inc
(NQ:
DTIL
)
10.10
-0.07 (-0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Precision Biosciences Inc
< Previous
1
2
3
4
5
Next >
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
March 09, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
March 02, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
February 24, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
February 22, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
There's a Lot of Upside For Emerging Gene-Editing Companies
February 21, 2023
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.
Via
MarketBeat
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
January 09, 2023
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
January 06, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
December 10, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Change to its Board of Directors
November 10, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
November 02, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
October 26, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
October 11, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
September 22, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Senior Leadership Organizational Changes
September 02, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
August 01, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 25, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock
June 27, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
June 28, 2022
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...
Via
FinancialNewsMedia
Precision BioSciences Announces $50 Million Offering of Common Stock
June 21, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
June 21, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
June 08, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022
June 03, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference
June 03, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2022
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.